Brief: Oncolytics Biotech Collaborates With Roche And Aio For Gastrointestinal Cancer Trial
27/10/2020 11:34
Oct 27 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® COLLABORATES WITH ROCHE AND AIO TO
INITIATE
A PHASE 1/2 GASTROINTESTINAL CANCER TRIAL COMBINING PELAREOREP
WITH ROCHE'S ANTI-PD-L1 CHECKPOINT INHIBITOR
* ONCOLYTICS - MULTI-CENTER TRIAL TO ASSESS SAFETY AND
EFFICACY OF
PELAREOREP-ATEZOLIZUMAB COMBINATION THERAPIES ACROSS MULTIPLE GI
CANCER INDICATIONS
* ONCOLYTICS BIOTECH INC - ANNOUNCED A NEW MULTI-INDICATION
GASTROINTESTINAL (GI) CANCER STUDY TO BE MANAGED BY AIO
Source text for Eikon: ID:nCNW32jTra
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer